Leerink Partners maintains Arcus Biosciences at Outperform, raises price target to $49 from $46
Leerink Partners kept Arcus Biosciences at Outperform, raising its price target to $49 from $46, a 6.5% increase. The target suggests 153.8% upside from the Nov 4 close of $19.31. Recent analyst notes on the company have price targets ranging from $40 to $50.
